The angiotensin II type 2 receptor (AGTR2) is a G protein-coupled receptor that plays a role in the renin-angiotensin system (RAS), counterbalancing the effects of the angiotensin II type 1 receptor (AGTR1). Primarily expressed during fetal development, AGTR2 is re-activated in adulthood under pathological conditions such as cardiovascular disease, tissue injury, and inflammation. It mediates vasodilation, anti-proliferative effects, and apoptosis, opposing AGTR1-driven vasoconstriction and fibrosis. AGTR2 signaling involves pathways like nitric oxide release, bradykinin potentiation, and modulation of potassium channels. Dysregulation of AGTR2 is implicated in hypertension, heart failure, renal disease, and neurodegenerative disorders. AGTR2 antibodies are essential tools for studying receptor localization, expression levels, and functional roles in experimental models. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate AGTR2's involvement in disease mechanisms and therapeutic targeting. Recent research explores AGTR2's potential in cancer progression and fibrotic diseases, highlighting its dual role as a protective or pathogenic mediator depending on the context. Validated AGTR2 antibodies aid in elucidating its complex interactions and developing RAS-targeted therapies.